ArticleCirculation. Heart failure2021
Novel Trial Design: CHIEF-HF.
Article in Circulation. Heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It reports registered trial NCT04252287. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Canagliflozin: Impact on Health Status, Quality of Life, and Functional Status in Heart Failure
Open the trial in the graphWho cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis.Cardiovascular diabetology · 2024Pooled it
- International Variation in Health Status Benefits in Patients Undergoing Initial Invasive Versus Conservative Management for Chronic Coronary Disease: Insights From the ISCHEMIA Trial.Circulation. Cardiovascular quality and outcomes · 2024Trial
- The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial.Nature medicine · 2022 · on this mapTrial
- Feasibility of decentralized real-world monitoring of SARS-CoV-2 booster vaccines and COVID-19 outcomes in myeloma.Blood advances · 2026Observational
- Clinical endpoints in pragmatic heart failure trials: From data collection to clinical endpoint classification.ESC heart failure · 2025Review
- Overcoming Disparities in Using SGLT2 Inhibitors for Cardiorenal Protection in Persons With and Without Type 2 Diabetes.The Journal of clinical endocrinology and metabolism · 2025Review
- Mobile Health Technology: (Smart)Watch and Wait.JACC. Case reports · 2023Article
- Decentralized Clinical Trials in Oncology: Are We Ready for a Virtual-First Paradigm?Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Leveraging Digital Health to Improve the Cardiovascular Health of Women.Current cardiovascular risk reports · 2023Review
- Novel Strategies to Improve Prescription of Guideline-Directed Medical Therapy in Heart Failure.Current treatment options in cardiovascular medicine · 2023Review
- The need for increased pragmatism in cardiovascular clinical trials.Nature reviews. Cardiology · 2022Review
- Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure?International journal of molecular sciences · 2022Review
- Preface to theme issue on pragmatic and virtual trials: Progress and challenges.Contemporary clinical trials · 2022Article
- Overview of trials from AHA 2021.Global cardiology science & practice · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
12 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe expense of clinical trials mandates new strategies to efficiently generate evidence and test novel therapies. In this context, we designed a decentralized, patient-centered randomized clinical trial leveraging mobile technologies, rather than in-person site visits, to test the efficacy of 12 weeks of canagliflozin for the treatment of heart failure, regardless of ejection fraction or diabetes status, on the reduction of heart failure symptoms.
methodsOne thousand nine hundred patients will be enrolled with a medical record-confirmed diagnosis of heart failure, stratified by reduced (≤40%) or preserved (>40%) ejection fraction and randomized 1:1 to 100 mg daily of canagliflozin or matching placebo. The primary outcome will be the 12-week change in the total symptom score of the Kansas City Cardiomyopathy Questionnaire. Secondary outcomes will be daily step count and other scales of the Kansas City Cardiomyopathy Questionnaire.
resultsThe trial is currently enrolling, even in the era of the coronavirus disease 2019 (COVID-19) pandemic.
conclusionsCHIEF-HF (Canagliflozin: Impact on Health Status, Quality of Life and Functional Status in Heart Failure) is deploying a novel model of conducting a decentralized, patient-centered, randomized clinical trial for a new indication for canagliflozin to improve the symptoms of patients with heart failure. It can model a new method for more cost-effectively testing the efficacy of treatments using mobile technologies with patient-reported outcomes as the primary clinical end point of the trial. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04252287.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.